Investigating the role of IL-17 and IL-22 in bacterial infections in COPD patients
Study of the Involvement of IL-17 / IL-22 Pathway in Bacterial Exacerbations of COPD
This study is trying to see how two immune pathways, IL-17 and IL-22, affect bacterial infections in people with COPD to help find better ways to manage their condition.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 4 sites (Lille and 3 other locations) |
| Trial ID | NCT02655302 on ClinicalTrials.gov |
What this trial studies
This study focuses on chronic obstructive pulmonary disease (COPD), a condition often exacerbated by bacterial infections. It aims to explore the involvement of the IL-17 and IL-22 immune pathways in these bacterial exacerbations. By analyzing lung function and collecting samples from hospitalized COPD patients, the study seeks to understand how a defective immune response contributes to bacterial colonization and infection in the airways. The findings could provide insights into potential therapeutic targets for managing COPD exacerbations.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with COPD who have been hospitalized for an exacerbation and are current or ex-smokers.
Not a fit: Patients with asthma, cystic fibrosis, or other chronic lung diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatments for COPD patients experiencing bacterial exacerbations.
How similar studies have performed: While the specific approach of targeting IL-17 and IL-22 in COPD exacerbations may be novel, similar studies have shown promise in understanding immune responses in chronic respiratory conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed COPD according GOLD guidelines * Current or ex-smoker (at least 10 pack-years) * Hospitalized for COPD exacerbation Exclusion Criteria: * Asthma or Cystic fibrosis * No other chronic lung disease * Solid Tumor unhealed or not considered in remission * Inhaled drug consumption * Women of childbearing potential without effective contraception * Pregnant or breastfeeding women * Incapable of consent * Lack of social security coverage
Where this trial is running
Lille and 3 other locations
- University hospital of Lille — Lille, France (Recruiting)
- Roubaix hospital — Roubaix, France (Recruiting)
- Seclin hospital — Seclin, France (Not_yet_recruiting)
- Tourcoing hospital — Tourcoing, France (Recruiting)
Study contacts
- Principal investigator: Nathalie Bautin, MD — University Hospital, Lille
- Study coordinator: Nathalie Bautin, MD
- Email: nathalie.bautin@chru-lille.fr
- Phone: 320444318
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.